Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment

Next Previous
X
Search
Trial Profile

A Phase 1/2 Study of EG-70 as an Intravesical Administration to Patients With BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) and High-Risk NMIBC Patients Who Are BCG Naïve or Received Incomplete BCG Treatment

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Detalimogene voraplasmid (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; First in man; Registrational; Therapeutic Use
  • Acronyms LEGEND STUDY
  • Sponsors enGene

    • Most Recent Events

    • 10 Sep 2024 According to an enGene media release, the Company expects to release preliminary data from the LEGEND study pivotal BCG-unresponsive cohort by the end of September.
    • 29 Aug 2024 According to an enGene media release, company will participate in several upcoming investor conferenced scheduled to take place in Sep 2024 and will present details from this pivotal trial.
    • 14 Jun 2024 According to an enGene media release, enGene expects to file a Biologics License Application (BLA) for EG-70 in mid-2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top